Host and vector-dependent effects on the risk of germline transmission of AAV vectors

Molecular Therapy

Volumn 17, Issue 6, 2009, Pages 1022-1030

  Favaro, Patricia ^a   Downey, Harre D ^a   Shangzhen Zhou, J ^a   Fraser Wright, J ^a,b   Hauck, Bernd ^a   Mingozzi, Federico ^a   High, Katherine A ^a,c,d   Arruda, Valder R ^a,d  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c HOWARD HUGHES MEDICAL INSTITUTE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; CAPSID PROTEIN;

ADENOVIRUS; ANIMAL; ARTICLE; CELL LINE; GENE VECTOR; GENETICS; GERM CELL; HISTOLOGY; HUMAN; LIVER; MALE; METABOLISM; RABBIT; SPERM; TESTIS; UROGENITAL SYSTEM; VASECTOMY;

ADENOVIRIDAE; ANIMALS; CAPSID PROTEINS; CELL LINE; FACTOR IX; GENETIC VECTORS; GERM CELLS; HUMANS; LIVER; MALE; RABBITS; SEMEN; TESTIS; UROGENITAL SYSTEM; VASECTOMY;

EID: 68149094149     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.56     Document Type: Article

References (36)

1. Jiang, H, Pierce, GF, Ozelo, MC, de Paula, EV, Vargas, JA, Smith, P et al. (2006). Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 14: 452-455.
2. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr., Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 358: 2240-2248.
3. Manno, CS, Pierce, GF, Arruda, VR, Glader, B, Ragni, M, Rasko, JJ et al. (2006). Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12: 342-347.
4. Nathwani, AC, Gray, JT, Ng, CY, Zhou, J, Spence, Y, Waddington, SN et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107: 2653-2661.
5. Schuettrumpf, J, Herzog, RW, Schlachterman, A, Kaufhold, A, Stafford, DW and Arruda, VR (2005). Factor IX variants improve gene therapy efficacy for hemophilia B. Blood 105: 2316-2323.
6. Arruda, VR, Fields, PA, Milner, R, Wainwright, L, De Miguel, MP, Donovan, PJ et al. (2001). Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 4: 586-592.
7. Schuettrumpf, J, Liu, JH, Couto, LB, Addya, K, Leonard, DG, Zhen, Z et al. (2006). Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. Mol Ther 13: 1064-1073.
8. Manno, CS, Chew, AJ, Hutchison, S, Larson, PJ, Herzog, RW, Arruda, VR et al. (2003). AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972.
9. Di Pasquale, G, Davidson, BL, Stein, CS, Martins, I, Scudiero, D, Monks, A et al. (2003). Identification of PDGFR as a receptor for AAV-5 transduction. Nat Med 9: 1306-1312.
10. Akache, B, Grimm, D, Pandey, K, Yant, SR, Xu, H and Kay, MA (2006). The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9. J Virol 80: 9831-9836.
11. Summerford, C and Samulski, RJ (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 72: 1438-1445.
12. Davidoff, AM, Gray, JT, Ng, CY, Zhang, Y, Zhou, J, Spence, Y et al. (2005). Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. Mol Ther 11: 875-888.
13. Xiao, W, Chirmule, N, Berta, SC, McCullough, B, Gao, G and Wilson, JM (1999). Gene therapy vectors based on adeno-associated virus type 1. J Virol 73: 3994-4003.
14. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
15. Moskalenko, M, Chen, L, van Roey, M, Donahue, BA, Snyder, RO, McArthur, JG et al. (2000). Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J Virol 74: 1761-1766.
16. Chirmule, N, Propert, K, Magosin, S, Qian, Y, Qian, R and Wilson, J (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 6: 1574-1583.
17. Blacklow, NR, Hoggan, MD, Sereno, MS, Brandt, CD, Kim, HW, Parrott, RH et al. (1971). A seroepidemiologic study of adenovirus-associated virus infection in infants and children. Am J Epidemiol 94: 359-366.
18. Brantly, ML, Spencer, LT, Humphries, M, Conlon, TJ, Spencer, CT, Poirier, A et al. (2006). Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 l-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther 17: 1177-1186.
19. Summerford, C, Bartlett, JS and Samulski, RJ (1999). αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat Med 5: 78-82.
20. Qing, K, Mah, C, Hansen, J, Zhou, S, Dwarki, V and Srivastava, A (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med 5: 71-77.
21. Jiang, H, Couto, LB, Patarroyo-White, S, Liu, T, Nagy, D, Vargas, JA et al. (2006). Effects of transient immunosuppression on adenoassociated, virus-mediated, liverdirected gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328.
22. Mingozzi, F, Hasbrouck, NC, Basner-Tschakarjan, E, Edmonson, SA, Hui, DJ, Sabatino, DE et al. (2007). Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110: 2334-2341.
23. Jiang, H, Lillicrap, D, Patarroyo-White, S, Liu, T, Qian, X, Scallan, CD et al. (2006). Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108: 107-115.
24. Wang, Z, Kuhr, CS, Allen, JM, Blankinship, M, Gregorevic, P, Chamberlain, JS et al. (2007). Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Mol Ther 15: 1160-1166.
25. Nathwani, AC, Davidoff, AM, Hanawa, H, Hu, Y, Hoffer, FA, Nikanorov, A et al. (2002). Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. Blood 100: 1662-1669.
26. Lozier, JN, Metzger, ME, Donahue, RE and Morgan, RA (1999). The rhesus macaque as an animal model for hemophilia B gene therapy. Blood 93: 1875-1881.
27. Mingozzi, F, Liu, YL, Dobrzynski, E, Kaufhold, A, Liu, JH, Wang, Y et al. (2003). Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111: 1347-1356.
28. Powell, JS, Ragni, MV, White, GC 2nd, Lusher, JM, Hillman-Wiseman, C, Moon, TE et al. (2003). Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 102: 2038-2045.
29. Roehl, HH, Leibbrandt, ME, Greengard, JS, Kamantigue, E, Glass, WG, Giedlin, M et al. (2000). Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. Hum Gene Ther 11: 2529-2540.
30. Mingozzi, F, Maus, MV, Hui, DJ, Sabatino, DE, Murphy, SL, Rasko, JE et al. (2007). CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 13: 419-422.
31. Scallan, CD, Jiang, H, Liu, T, Patarroyo-White, S, Sommer, JM, Zhou, S et al. (2006). Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107: 1810-1817.
32. Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ et al. (1998). Adeno-associated virus vectors can be efficiently produced without helper virus. Gene Ther 5: 938-945.
33. Le, M, Okuyama, T, Cai, SR, Kennedy, SC, Bowling, WM, Flye, MW et al. (1997). Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 89: 1254-1259.
34. Hauck, B, Chen, L and Xiao, W (2003). Generation and characterization of chimeric recombinant AAV vectors. Mol Ther 7: 419-425.
35. Wright, JF, Le, T, Prado, J, Bahr-Davidson, J, Smith, PH, Zhen, Z et al. (2005). Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation. Mol Ther 12: 171-178.
36. Sommer, JM, Smith, PH, Parthasarathy, S, Isaacs, J, Vijay, S, Kieran, J et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 7: 122-128.